Loading patent…
AssigneesHarbour Antibodies BV, Universiteit Utrecht Holding B.V.
InventorsFranklin Gerardus Grosveld, Dubravka Drabek, Rien Van Haperen, Berend Jan Bosch, Juliette Fedry, Daniel L. Hurdiss, Thijs Kuiken, Batholomeus Leonardus Haagmans, Barry Hubertus Gerardus Rockx
Estimating the term…
The invention relates to antibodies and antigen-binding fragments thereof that recognize SARS-Cov-2 spike proteins (SARS2-S). In some embodiments, the antibodies bind to SARS2-S with high affinity and/or inhibit SARS-Cov-2 infection of human cells. in some embodiments, the antibodies provide a means of preventing, treating or ameliorating SARS2 infection, In some embodiments, the antibodies are used in diagnostic assays (e.g. serodiagnostic assays for SARS2).
An antibody that binds to SARS-Cov-2 coronavirus spike protein (SARS2-S), wherein the antibody is a fully human IgG antibody, and wherein the antibody comprises two heavy and two light chains, wherein each heavy chain comprises a CDR1 comprising an amino acid sequence set forth as SEQ ID NO:
An antibody that binds to SARS-Cov-2 coronavirus spike protein (SARS2-S), wherein the antibody is a fully human IgG antibody, and wherein the antibody comprises two heavy and two light chains, wherein each heavy chain comprises a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO:
An IgG1 antibody that binds to SARS-Cov-2 coronavirus spike protein (SARS2-S), wherein the antibody comprises two heavy and two light chains, wherein each heavy chain comprises the amino acid sequence set forth as SEQ ID NO:
Dependencies are inferred from the claim text.